These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25948583)

  • 1. SELPHI: correlation-based identification of kinase-associated networks from global phospho-proteomics data sets.
    Petsalaki E; Helbig AO; Gopal A; Pasculescu A; Roth FP; Pawson T
    Nucleic Acids Res; 2015 Jul; 43(W1):W276-82. PubMed ID: 25948583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deep Phosphotyrosine Proteomics by Optimization of Phosphotyrosine Enrichment and MS/MS Parameters.
    Abe Y; Nagano M; Tada A; Adachi J; Tomonaga T
    J Proteome Res; 2017 Feb; 16(2):1077-1086. PubMed ID: 28152594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
    Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.
    Serizawa M; Takahashi T; Yamamoto N; Koh Y
    J Thorac Oncol; 2013 Mar; 8(3):259-69. PubMed ID: 23334091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells.
    Weber C; Schreiber TB; Daub H
    J Proteomics; 2012 Feb; 75(4):1343-56. PubMed ID: 22115753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bidirectional signaling between TM4SF5 and IGF1R promotes resistance to EGFR kinase inhibitors.
    Choi J; Kang M; Nam SH; Lee GH; Kim HJ; Ryu J; Cheong JG; Jung JW; Kim TY; Lee HY; Lee JW
    Lung Cancer; 2015 Oct; 90(1):22-31. PubMed ID: 26190015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative phospho-proteomic profiling of hepatocyte growth factor (HGF)-MET signaling in colorectal cancer.
    Organ SL; Tong J; Taylor P; St-Germain JR; Navab R; Moran MF; Tsao MS
    J Proteome Res; 2011 Jul; 10(7):3200-11. PubMed ID: 21609022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From Phosphosites to Kinases.
    Munk S; Refsgaard JC; Olsen JV; Jensen LJ
    Methods Mol Biol; 2016; 1355():307-21. PubMed ID: 26584935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
    Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
    Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition.
    Koch H; Busto ME; Kramer K; Médard G; Kuster B
    J Proteome Res; 2015 Jun; 14(6):2617-25. PubMed ID: 25963923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
    Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
    Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. piNET: a versatile web platform for downstream analysis and visualization of proteomics data.
    Shamsaei B; Chojnacki S; Pilarczyk M; Najafabadi M; Niu W; Chen C; Ross K; Matlock A; Muhlich J; Chutipongtanate S; Zheng J; Turner J; Vidović D; Jaffe J; MacCoss M; Wu C; Pillai A; Ma'ayan A; Schürer S; Kouril M; Medvedovic M; Meller J
    Nucleic Acids Res; 2020 Jul; 48(W1):W85-W93. PubMed ID: 32469073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NetworKIN: a resource for exploring cellular phosphorylation networks.
    Linding R; Jensen LJ; Pasculescu A; Olhovsky M; Colwill K; Bork P; Yaffe MB; Pawson T
    Nucleic Acids Res; 2008 Jan; 36(Database issue):D695-9. PubMed ID: 17981841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.
    Li H; Wang S; Takayama K; Harada T; Okamoto I; Iwama E; Fujii A; Ota K; Hidaka N; Kawano Y; Nakanishi Y
    Lung Cancer; 2015 Apr; 88(1):1-8. PubMed ID: 25670150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.
    Morgillo F; Woo JK; Kim ES; Hong WK; Lee HY
    Cancer Res; 2006 Oct; 66(20):10100-11. PubMed ID: 17047074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M; He CS; Wei SH; Zhang L
    Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.